Abstract
Targeted protein degradation (TPD) technologies represent a groundbreaking approach in cancer therapy, focusing on the selective degradation of oncogenic proteins such as BCL6 and SMARCA2. By leveraging the ubiquitin-proteasome system, TPD offers a novel strategy that surpasses traditional therapies' limitations, targeting the core mechanisms of oncogenesis. This article explores the significant advancements in TPD, detailing innovative strategies for the degradation of essential proteins implicated in cancer, and discusses the potential of these approaches to transform cancer treatment through precision medicine and personalized therapy.